Good morning, everyone, and how are you today? We are doing just fine, thank you, now that the Pharmalot campus has quieted down. One short person has left for gainful employment, the other is sleeping in, and our official mascot is curled in a corner waiting for treats. Such a life, yes? Have no fear. We have treats for you as well — the menu of tidbits assembled below. Along with a cup of stimulation, this can be a fine way to start the day. On that note, we hope you conquer the world and, of course, do keep in touch …

Endo International (ENDP) and Allergan (AGN) are in talks to avoid going to a landmark trial set to begin in October over the opioid crisis, according to the Wall Street Journal. Endo is close to finalizing a $10 million deal, and Allergan is in negotiations for a potential $5 million deal that would settle claims over its branded drugs but may not entirely eliminate it from the trial. The settlements, if finalized, would bring the companies in accord with two Ohio counties whose claims have been chosen to serve as bellwethers in litigation over the opioid crisis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy